Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of MK-7684A plus concurrent chemoradiotherapy followed by MK-7684A versus concurrent chemoradiotherapy followed by durvalumab in unresectable stage III locally advanced non-small cell lung cancer
MOH_2022-03-01_010636Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing MK-7684A arm with Durvalumab control arm (2 arms). Primary endpoints: Safety, Efficacy and 1 more. Started Jan 2022; status: completed.
02
Drugs
vibostolimab + pembrolizumabdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2022-03-01_010636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-03-01_010636.